Hospital
University Health Shreveport LLC
University Health Shreveport LLC was paid $98.06M by Medicaid between Jul 2018 and Dec 2024, across 551 billing codes. Its largest line is 99285, emergency room visit (most serious) — 9.1% of everything it billed.
33Billing provider infoUNIVERSITY HEALTH SHREVEPORT LLC
SHREVEPORT, LA 71103
SHREVEPORT, LA 71103
33aNPI1427536325assigned 08/02/2018
33bProvider typeGeneral Acute Care Hospital
28Total paid$98.06M
24GClaims2,713,359
24DCodes billed551
24AFirst – last monthJul 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Louisiana
Rank by total paid#3 of 96
Median peer was paid$5.17M
This provider vs. median19×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 102,881 | $1.60M | |
| 2019 | 411,587 | $8.40M | |
| 2020 | 322,854 | $10.16M | |
| 2021 | 476,124 | $19.19M | |
| 2022 | 462,568 | $19.24M | |
| 2023 | 499,079 | $22.14M | |
| 2024incomplete | 438,266 | $17.32M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.1% | 24,484 | 22,356 | $8.91M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 7.8% | 239,900 | 211,410 | $7.60M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 7.7% | 159,470 | 145,168 | $7.58M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.1% | 30,454 | 27,747 | $7.00M |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 5.3% | 115,091 | 105,126 | $5.23M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 5.1% | 181,894 | 160,101 | $5.01M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 4.8% | 34,364 | 31,853 | $4.72M |
| J9312 | Injection, rituximab, 10 mg | 2.3% | 968 | 536 | $2.30M |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | 1.9% | 2,205 | 1,905 | $1.83M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.8% | 4,887 | 4,561 | $1.80M |
| J0490 | Injection, belimumab, 10 mg | 1.7% | 947 | 569 | $1.67M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.6% | 25,095 | 13,620 | $1.58M |
539 more codes
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.5% | 53,595 | $1.44M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.4% | 5,074 | $1.37M |
| 80053 | Comprehensive metabolic panel | 1.4% | 185,640 | $1.37M |
| 41899 | Unlisted procedure, dentoalveolar structures | 1.4% | 3,286 | $1.37M |
| J9271 | Injection, pembrolizumab, 1 mg | 1.3% | 333 | $1.32M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.2% | 46,617 | $1.21M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.1% | 10,120 | $1.06M |
| 67028 | Intravitreal injection of a pharmacologic agent | 1.0% | 6,173 | $986K |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | <1% | 285 | $973K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 31,601 | $971K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 31,627 | $964K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 171,010 | $921K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 11,694 | $886K |
| J3262 | Injection, tocilizumab, 1 mg | <1% | 1,003 | $872K |
| 31231 | <1% | 2,417 | $797K | |
| 36430 | <1% | 2,902 | $750K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 17,878 | $718K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 21,565 | $703K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 10,786 | $623K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 1,736 | $603K |
| 36415 | Collection of venous blood by venipuncture | <1% | 275,727 | $584K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 4,600 | $583K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 8,944 | $581K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 142 | $572K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 7,972 | $541K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 17,596 | $523K |
| 77385 | <1% | 1,282 | $490K | |
| 54150 | <1% | 1,312 | $490K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 1,645 | $470K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 9,472 | $445K |
| 92134 | <1% | 13,329 | $415K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,798 | $411K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 1,244 | $381K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 692 | $367K |
| 94375 | <1% | 3,923 | $336K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 48,511 | $333K |
| 87536 | <1% | 5,503 | $328K | |
| 80061 | Lipid panel | <1% | 32,596 | $326K |
| G0378 | Hospital observation service, per hour | <1% | 2,432 | $320K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 15,867 | $319K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 1,807 | $317K |
| 77386 | <1% | 1,251 | $289K | |
| 80074 | <1% | 10,098 | $288K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 6,455 | $287K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 659 | $284K |
| 73130 | <1% | 3,805 | $264K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 6,043 | $245K |
| 31575 | <1% | 1,182 | $245K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 3,104 | $236K |
| 20610 | <1% | 1,623 | $214K | |
| 31579 | <1% | 1,051 | $204K | |
| J9395 | Injection, fulvestrant, 25 mg | <1% | 303 | $197K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 1,741 | $194K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 9,267 | $188K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,339 | $183K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 15,028 | $182K |
| 92083 | <1% | 6,074 | $180K | |
| 81025 | <1% | 30,090 | $179K | |
| 31237 | <1% | 512 | $178K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 2,509 | $173K |
| 86481 | <1% | 2,938 | $172K | |
| J0741 | Injection, cabotegravir and rilpivirine, 2mg/3mg | <1% | 40 | $168K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 494 | $160K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 5,736 | $159K |
| 54161 | <1% | 606 | $158K | |
| 92133 | <1% | 7,217 | $157K | |
| 93017 | <1% | 1,046 | $142K | |
| 95811 | <1% | 353 | $141K | |
| 93458 | <1% | 45 | $132K | |
| 82728 | <1% | 13,765 | $129K | |
| 71271 | <1% | 799 | $127K | |
| 90686 | <1% | 14,688 | $126K | |
| 93325 | <1% | 1,508 | $124K | |
| 67228 | <1% | 623 | $124K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,967 | $117K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 4,618 | $116K |
| 51798 | <1% | 1,008 | $110K | |
| 73030 | <1% | 1,449 | $109K | |
| 86780 | <1% | 9,343 | $105K | |
| 87522 | Neg quan hep c or qual rna | <1% | 3,347 | $104K |
| 73630 | <1% | 1,518 | $103K | |
| 92557 | <1% | 1,631 | $102K | |
| 77336 | <1% | 2,507 | $100K | |
| 59025 | Fetal non-stress test | <1% | 1,850 | $100K |
| 73610 | <1% | 1,890 | $97K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,875 | $97K |
| 93304 | <1% | 511 | $96K | |
| J1459 | Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | <1% | 49 | $95K |
| V2632 | Posterior chamber intraocular lens | <1% | 1,500 | $94K |
| 57454 | <1% | 320 | $86K | |
| 95117 | <1% | 4,619 | $85K | |
| 76801 | <1% | 1,600 | $85K | |
| 86361 | <1% | 4,344 | $85K | |
| 73562 | <1% | 1,313 | $84K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,286 | $83K |
| 85027 | <1% | 17,231 | $83K | |
| 91200 | <1% | 941 | $81K | |
| 73502 | <1% | 1,311 | $81K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 12,572 | $80K |
| 86803 | <1% | 6,699 | $79K | |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 171 | $78K |
| 90677 | <1% | 777 | $77K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 1,040 | $76K |
| 86160 | <1% | 10,034 | $74K | |
| 84439 | <1% | 10,683 | $73K | |
| 80050 | General health panel | <1% | 1,927 | $70K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,465 | $70K |
| 73564 | <1% | 899 | $70K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 78 | $68K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 4,650 | $67K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 606 | $64K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 477 | $62K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,590 | $61K |
| 65855 | <1% | 209 | $60K | |
| 96367 | <1% | 2,078 | $59K | |
| 86140 | <1% | 14,990 | $57K | |
| 93296 | <1% | 3,714 | $55K | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 68 | $55K |
| C1776 | Joint device (implantable) | <1% | 36 | $54K |
| 94150 | <1% | 498 | $54K | |
| 99195 | <1% | 1,392 | $54K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,501 | $51K |
| 81000 | <1% | 18,907 | $51K | |
| 72100 | <1% | 755 | $50K | |
| 90378 | <1% | 141 | $50K | |
| 70355 | <1% | 1,147 | $50K | |
| 93321 | <1% | 584 | $49K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 225 | $49K |
| C1769 | Guide wire | <1% | 2,031 | $49K |
| 36591 | <1% | 883 | $48K | |
| 73110 | <1% | 835 | $47K | |
| 69210 | <1% | 802 | $47K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,979 | $47K |
| 86225 | <1% | 4,779 | $47K | |
| 90715 | <1% | 1,751 | $46K | |
| 76813 | <1% | 483 | $46K | |
| 0002A | <1% | 1,409 | $46K | |
| 66982 | <1% | 82 | $45K | |
| 93299 | <1% | 139 | $45K | |
| 86703 | <1% | 4,108 | $45K | |
| 86235 | <1% | 3,102 | $44K | |
| 0001A | <1% | 1,347 | $43K | |
| 92612 | <1% | 652 | $42K | |
| 95012 | <1% | 847 | $42K | |
| 93320 | <1% | 493 | $42K | |
| 92020 | <1% | 4,584 | $42K | |
| 76770 | <1% | 511 | $40K | |
| 97161 | <1% | 847 | $39K | |
| 96415 | <1% | 1,582 | $38K | |
| 73560 | <1% | 366 | $36K | |
| 82570 | <1% | 9,998 | $36K | |
| 74178 | <1% | 101 | $36K | |
| 76830 | Ultrasound, transvaginal | <1% | 770 | $35K |
| 95115 | <1% | 1,855 | $35K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 1,317 | $35K |
| 81003 | <1% | 19,151 | $35K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 493 | $35K |
| 95812 | <1% | 167 | $34K | |
| 76775 | <1% | 534 | $33K | |
| 84466 | <1% | 3,473 | $33K | |
| 82550 | <1% | 6,141 | $33K | |
| 86850 | <1% | 7,966 | $33K | |
| 85651 | <1% | 10,129 | $33K | |
| 84484 | <1% | 3,901 | $32K | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 1,803 | $32K |
| 92567 | <1% | 2,501 | $31K | |
| 76820 | <1% | 799 | $31K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 145 | $30K |
| 85045 | <1% | 9,849 | $30K | |
| 83970 | <1% | 1,310 | $30K | |
| 87902 | <1% | 192 | $30K | |
| 96409 | <1% | 256 | $29K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 853 | $29K |
| 90651 | <1% | 147 | $28K | |
| 81002 | <1% | 11,040 | $28K | |
| 83655 | <1% | 2,397 | $27K | |
| 86706 | <1% | 3,859 | $27K | |
| 86003 | <1% | 631 | $27K | |
| 94664 | <1% | 978 | $26K | |
| 85610 | <1% | 10,942 | $25K | |
| 83735 | <1% | 6,070 | $25K | |
| 64615 | <1% | 322 | $23K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 520 | $23K |
| 77300 | <1% | 239 | $23K | |
| 83540 | <1% | 4,945 | $22K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 118 | $22K |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 646 | $21K |
| 85660 | <1% | 4,773 | $21K | |
| 86920 | <1% | 982 | $21K | |
| 82248 | <1% | 5,056 | $21K | |
| 86762 | <1% | 1,585 | $20K | |
| 73552 | <1% | 369 | $20K | |
| 85046 | <1% | 4,592 | $20K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 16,581 | $20K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,417 | $19K |
| 77338 | <1% | 191 | $18K | |
| 84156 | <1% | 7,152 | $18K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 50 | $18K |
| 80069 | <1% | 3,486 | $18K | |
| 96161 | <1% | 1,026 | $18K | |
| 87340 | <1% | 2,058 | $18K | |
| 73590 | <1% | 338 | $17K | |
| 93356 | <1% | 104 | $16K | |
| 85007 | <1% | 7,369 | $16K | |
| 71250 | <1% | 115 | $16K | |
| 86900 | <1% | 7,929 | $16K | |
| 95819 | <1% | 129 | $16K | |
| 86901 | <1% | 7,942 | $16K | |
| 81001 | <1% | 6,715 | $15K | |
| 90656 | <1% | 2,501 | $15K | |
| 86038 | <1% | 1,548 | $15K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 135 | $15K |
| 52000 | <1% | 58 | $14K | |
| 86704 | <1% | 1,557 | $14K | |
| 88184 | <1% | 697 | $13K | |
| J0185 | Injection, aprepitant, 1 mg | <1% | 44 | $12K |
| 82962 | <1% | 5,955 | $12K | |
| 94618 | <1% | 193 | $12K | |
| 97165 | <1% | 224 | $12K | |
| 80055 | <1% | 574 | $12K | |
| 77301 | <1% | 17 | $12K | |
| 94660 | <1% | 185 | $11K | |
| 86200 | <1% | 1,061 | $11K | |
| 16020 | <1% | 57 | $11K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 49 | $11K |
| 86039 | <1% | 1,190 | $11K | |
| 80081 | <1% | 187 | $11K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,110 | $11K |
| 86592 | <1% | 3,153 | $10K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 130 | $10K |
| 85730 | <1% | 2,457 | $10K | |
| 97602 | <1% | 115 | $10K | |
| 72040 | <1% | 116 | $10K | |
| 75726 | <1% | 14 | $10K | |
| 80076 | <1% | 1,486 | $10K | |
| 96402 | <1% | 505 | $9K | |
| 83880 | <1% | 368 | $9K | |
| 80320 | <1% | 1,369 | $9K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 456 | $9K |
| 84153 | <1% | 741 | $9K | |
| 84100 | <1% | 2,892 | $9K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 179 | $9K |
| 82330 | <1% | 1,511 | $8K | |
| 97597 | <1% | 328 | $8K | |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 303 | $8K |
| 83550 | <1% | 1,380 | $8K | |
| 82565 | <1% | 2,793 | $8K | |
| J0178 | Injection, aflibercept, 1 mg | <1% | 1,797 | $8K |
| 82043 | <1% | 1,982 | $8K | |
| 36000 | <1% | 310 | $8K | |
| 87210 | <1% | 1,850 | $8K | |
| 83615 | <1% | 1,852 | $8K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,288 | $7K |
| 87901 | <1% | 36 | $7K | |
| 86708 | <1% | 750 | $7K | |
| 30520 | <1% | 27 | $7K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 35 | $7K |
| 94010 | <1% | 72 | $7K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 15 | $6K |
| 82784 | <1% | 829 | $6K | |
| 82607 | <1% | 547 | $6K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 156 | $6K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 195 | $6K |
| 90739 | <1% | 60 | $6K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,290 | $6K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 37 | $6K |
| 83690 | <1% | 1,105 | $6K | |
| 99152 | <1% | 9,943 | $6K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 178 | $6K |
| 0003A | <1% | 159 | $6K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 12 | $6K |
| 99153 | Mod sedat endo service >5yrs | <1% | 2,771 | $6K |
| 0004A | <1% | 145 | $5K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,846 | $5K |
| 84702 | <1% | 379 | $5K | |
| 73521 | <1% | 53 | $5K | |
| 82105 | <1% | 333 | $5K | |
| 97750 | <1% | 535 | $5K | |
| 77072 | <1% | 90 | $5K | |
| 71270 | <1% | 28 | $5K | |
| 96401 | <1% | 141 | $5K | |
| 72110 | <1% | 80 | $5K | |
| 11055 | <1% | 254 | $5K | |
| 92504 | <1% | 229 | $5K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 107 | $5K |
| 87081 | <1% | 749 | $5K | |
| 86431 | <1% | 1,022 | $5K | |
| 73620 | <1% | 27 | $5K | |
| 11056 | <1% | 169 | $5K | |
| 70486 | <1% | 212 | $5K | |
| 74019 | <1% | 56 | $4K | |
| 80280 | <1% | 219 | $4K | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 482 | $4K |
| 10005 | <1% | 15 | $4K | |
| 86922 | <1% | 142 | $4K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 36,002 | $4K |
| 36902 | <1% | 52 | $4K | |
| 82746 | <1% | 375 | $4K | |
| 92136 | <1% | 167 | $4K | |
| 85014 | <1% | 2,530 | $4K | |
| 87529 | <1% | 152 | $4K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 75 | $4K |
| 84481 | <1% | 445 | $4K | |
| 72200 | <1% | 53 | $4K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,364 | $4K |
| 94060 | <1% | 38 | $3K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 93 | $3K |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 378 | $3K |
| 93298 | <1% | 182 | $3K | |
| G0127 | Trimming of dystrophic nails, any number | <1% | 1,041 | $3K |
| 97760 | <1% | 210 | $3K | |
| 84163 | <1% | 223 | $3K | |
| J3490 | Unclassified drugs | <1% | 954 | $3K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 13,591 | $3K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,658 | $3K |
| 76514 | <1% | 197 | $3K | |
| 88307 | <1% | 73 | $3K | |
| 76937 | <1% | 202 | $3K | |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 13 | $3K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 52 | $3K |
| 65222 | <1% | 28 | $3K | |
| 51705 | <1% | 14 | $3K | |
| 77334 | <1% | 41 | $3K | |
| 99157 | <1% | 1,334 | $3K | |
| Q9956 | Injection, octafluoropropane microspheres, per ml | <1% | 86 | $3K |
| 86355 | <1% | 126 | $3K | |
| 74018 | <1% | 61 | $3K | |
| 84550 | <1% | 714 | $2K | |
| 40800 | <1% | 12 | $2K | |
| 77280 | <1% | 29 | $2K | |
| 87634 | <1% | 37 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 329 | $2K |
| 90732 | <1% | 54 | $2K | |
| 85018 | <1% | 979 | $2K | |
| 86336 | <1% | 154 | $2K | |
| 93246 | <1% | 29 | $2K | |
| 82374 | <1% | 1,013 | $2K | |
| 84132 | <1% | 1,058 | $2K | |
| 80299 | <1% | 180 | $2K | |
| 84295 | <1% | 1,016 | $2K | |
| 84520 | <1% | 1,404 | $2K | |
| 93297 | <1% | 234 | $2K | |
| 82435 | <1% | 1,007 | $2K | |
| 84460 | <1% | 500 | $2K | |
| 82947 | <1% | 1,361 | $2K | |
| 94729 | <1% | 16 | $2K | |
| 73080 | <1% | 38 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 935 | $2K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 54 | $2K |
| 84075 | <1% | 473 | $2K | |
| 88142 | <1% | 143 | $2K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 19,874 | $2K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 40 | $2K |
| 80230 | <1% | 94 | $2K | |
| 88720 | <1% | 512 | $2K | |
| 87070 | <1% | 237 | $2K | |
| 84450 | <1% | 488 | $2K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 48 | $2K |
| 00920 | <1% | 597 | $2K | |
| 94760 | <1% | 1,931 | $2K | |
| 87900 | <1% | 14 | $2K | |
| 87906 | <1% | 14 | $2K | |
| 94726 | <1% | 16 | $2K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 30 | $2K |
| 82247 | <1% | 515 | $2K | |
| 86905 | <1% | 557 | $2K | |
| 73120 | <1% | 24 | $2K | |
| 91010 | <1% | 14 | $2K | |
| 83516 | <1% | 167 | $2K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 308 | $2K |
| 99156 | <1% | 2,999 | $2K | |
| 82950 | <1% | 598 | $2K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 312 | $1K |
| 82977 | <1% | 239 | $1K | |
| 72120 | <1% | 33 | $1K | |
| 92228 | <1% | 94 | $1K | |
| 82542 | <1% | 81 | $1K | |
| 82785 | <1% | 121 | $1K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 556 | $1K |
| 86593 | <1% | 379 | $1K | |
| 84155 | <1% | 504 | $1K | |
| 96380 | <1% | 480 | $1K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,841 | $1K |
| 94762 | <1% | 23 | $1K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 780 | $1K |
| 96112 | <1% | 573 | $1K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 241 | $1K |
| 83021 | <1% | 74 | $1K | |
| 0054A | <1% | 40 | $1K | |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 15 | $1K |
| 92250 | <1% | 22 | $1K | |
| 92613 | <1% | 151 | $1K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 119 | $997.84 |
| J2704 | Injection, propofol, 10 mg | <1% | 18,044 | $996.28 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 171 | $938.28 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,464 | $921.61 |
| 82077 | <1% | 96 | $893.55 | |
| 87186 | <1% | 133 | $890.95 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,873 | $810.69 |
| 76642 | <1% | 13 | $806.08 | |
| 86360 | <1% | 33 | $802.17 | |
| 90714 | <1% | 50 | $792.16 | |
| 87077 | <1% | 199 | $791.84 | |
| 80047 | <1% | 122 | $788.45 | |
| 99070 | <1% | 375 | $759.54 | |
| 83520 | <1% | 73 | $755.82 | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 14 | $753.72 |
| 92025 | <1% | 15 | $747.45 | |
| A9698 | Non-radioactive contrast imaging material, not otherwise classified, per study | <1% | 180 | $729.03 |
| 97166 | <1% | 19 | $723.61 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 14 | $716.76 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,911 | $705.97 |
| Q0111 | Wet mounts, including preparations of vaginal, cervical or skin specimens | <1% | 1,288 | $694.78 |
| 66174 | <1% | 92 | $679.83 | |
| 76000 | <1% | 146 | $674.17 | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 174 | $673.86 |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 33 | $657.98 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 17 | $652.25 |
| 88342 | <1% | 2,026 | $633.97 | |
| 83521 | <1% | 82 | $586.59 | |
| 82397 | <1% | 143 | $581.77 | |
| 83020 | <1% | 48 | $566.28 | |
| 86357 | <1% | 33 | $562.41 | |
| J9250 | Methotrexate sodium, 5 mg | <1% | 60 | $559.59 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,522 | $549.28 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 393 | $539.26 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 85 | $525.62 |
| 86359 | <1% | 33 | $520.75 | |
| 97010 | <1% | 715 | $504.60 | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 85 | $503.22 |
| 72170 | <1% | 12 | $502.74 | |
| C9257 | Injection, bevacizumab, 0.25 mg | <1% | 2,577 | $490.99 |
| 88173 | <1% | 40 | $481.52 | |
| 87517 | <1% | 13 | $471.24 | |
| 87486 | <1% | 12 | $467.88 | |
| 87581 | <1% | 12 | $467.88 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 134 | $456.46 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 762 | $440.87 |
| 0053A | <1% | 18 | $429.58 | |
| J9260 | Injection, methotrexate sodium, 50 mg | <1% | 56 | $400.95 |
| 86790 | <1% | 39 | $399.28 | |
| 83002 | <1% | 33 | $399.26 | |
| 86677 | <1% | 28 | $382.05 | |
| 86364 | <1% | 85 | $380.60 | |
| 86258 | <1% | 85 | $380.60 | |
| 99188 | <1% | 901 | $380.56 | |
| 84403 | <1% | 17 | $361.34 | |
| 0052A | <1% | 27 | $356.02 | |
| 11719 | <1% | 26 | $326.23 | |
| 83498 | <1% | 14 | $326.04 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 681 | $319.19 |
| J9035 | Injection, bevacizumab, 10 mg | <1% | 1,171 | $292.00 |
| 82150 | <1% | 49 | $278.28 | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 17 | $275.05 |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 154 | $264.67 |
| 88141 | <1% | 15 | $246.87 | |
| 0051A | <1% | 22 | $245.68 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,352 | $242.32 |
| 90480 | <1% | 13 | $238.70 | |
| 82085 | <1% | 28 | $233.04 | |
| 80164 | <1% | 30 | $231.36 | |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 79 | $225.05 |
| 88172 | <1% | 41 | $222.12 | |
| A6457 | Tubular dressing with or without elastic, any width, per linear yard | <1% | 19 | $213.12 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 382 | $195.86 |
| 86430 | <1% | 49 | $188.68 | |
| 01992 | <1% | 29 | $187.37 | |
| 80143 | <1% | 13 | $181.74 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 365 | $181.69 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 30 | $179.71 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 17 | $176.96 |
| 83010 | <1% | 19 | $154.44 | |
| 86707 | <1% | 14 | $138.84 | |
| 87350 | <1% | 14 | $138.36 | |
| 00120 | <1% | 17 | $127.65 | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 55 | $122.52 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 178 | $114.67 |
| 87341 | <1% | 13 | $113.63 | |
| 76942 | <1% | 14 | $113.36 | |
| 96111 | <1% | 18 | $110.76 | |
| 84480 | <1% | 17 | $109.62 | |
| 90694 | <1% | 86 | $108.91 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 143 | $108.87 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 371 | $105.09 |
| 81511 | <1% | 94 | $100.21 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 22 | $89.78 |
| 88177 | <1% | 19 | $85.05 | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 70 | $61.26 |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 16 | $61.26 |
| 36416 | <1% | 38 | $60.95 | |
| 82310 | <1% | 18 | $56.76 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 2,685 | $56.50 |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 34 | $55.05 |
| 87205 | <1% | 14 | $54.60 | |
| 83883 | <1% | 19 | $54.23 | |
| 90670 | <1% | 829 | $46.85 | |
| 84165 | <1% | 14 | $42.96 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 773 | $42.76 |
| 81508 | <1% | 193 | $39.43 | |
| C1819 | Surgical tissue localization and excision device (implantable) | <1% | 27 | $38.14 |
| 82040 | <1% | 17 | $29.70 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 49 | $13.50 |
| 90685 | <1% | 815 | $4.62 | |
| 91300 | <1% | 2,783 | $3.60 | |
| 90680 | 0% | 317 | $0.00 | |
| 77001 | 0% | 43 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 430 | $0.00 |
| 00142 | 0% | 965 | $0.00 | |
| J1597 | Injection, glycopyrrolate (glyrx-pf), 0.1 mg | 0% | 33 | $0.00 |
| 88341 | 0% | 25 | $0.00 | |
| A4217 | Sterile water/saline, 500 ml | 0% | 197 | $0.00 |
| A9270 | Non-covered item or service | 0% | 227 | $0.00 |
| 90723 | 0% | 483 | $0.00 | |
| 90636 | 0% | 121 | $0.00 | |
| Q3014 | Telehealth originating site facility fee | 0% | 29 | $0.00 |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 13 | $0.00 |
| 00126 | 0% | 17 | $0.00 | |
| 00160 | 0% | 33 | $0.00 | |
| 91305 | 0% | 85 | $0.00 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 41 | $0.00 |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | 0% | 18 | $0.00 |
| 88304 | 0% | 24 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 15 | $0.00 |
| 90620 | 0% | 26 | $0.00 | |
| G0009 | Administration of pneumococcal vaccine | 0% | 14 | $0.00 |
| V2787 | Astigmatism correcting function of intraocular lens | 0% | 174 | $0.00 |
| 90633 | 0% | 286 | $0.00 | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | 0% | 1,587 | $0.00 |
| 90653 | 0% | 26 | $0.00 | |
| 90648 | 0% | 811 | $0.00 | |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | 0% | 116 | $0.00 |
| C1752 | Catheter, hemodialysis/peritoneal, short-term | 0% | 218 | $0.00 |
| C1876 | Stent, non-coated/non-covered, with delivery system | 0% | 15 | $0.00 |
| 82172 | 0% | 27 | $0.00 | |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | 0% | 21 | $0.00 |
| C1758 | Catheter, ureteral | 0% | 14 | $0.00 |
| 00731 | 0% | 35 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 13 | $0.00 |
| J2720 | Injection, protamine sulfate, per 10 mg | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGREEN, MITZI (DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| LSU Health Sciences Center Shreveport Faculty Group Practice | Shreveport, LA | $235.66M |
| BRFHH Monroe LLC | Monroe, LA | $56.71M |
| Ochsner LSU Health Shreveport - ST. Mary Medical Center, LLC | Shreveport, LA | $15.02M |
| BRFHH Monroe LLC | Monroe, LA | $8.82M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.